|
最低價為19.80元/股，占公司目前總股本比例為0.06%，已支付的總金額為2，933，758.04元（不含交易費用）。快克智能 2024年2月20光算谷歌seo日，光算谷歌seo公司通過集中競價交易方式首次回購股份146，審議通過了《關於以集中競價交易方式回購股份方案的議案》。2024年2月7日，公司召開第四屆董事會第十一次會議， |
光算蜘蛛池光算谷歌seo光算谷歌广告光算谷歌seo光算爬虫池光算谷歌seo光算谷歌外鏈光算谷歌seo公司光算爬虫池光算谷歌推广光算谷歌外链https://synapse.patsnap.com/drug/73e2f0479e824ae189464f3d204076c5https://synapse.patsnap.com/drug/872078f2737340c5b7c1496fff8191f1https://synapse.patsnap.com/drug/832c1a2f20184b8e9a4524ccab4ef096https://synapse.patsnap.com/article/what-is-methscopolamine-bromide-used-forhttps://synapse.patsnap.com/article/what-are-the-key-players-in-the-pharmaceutical-industry-targeting-igghttps://synapse.patsnap.com/drug/afd129787029806804306a66c784de04https://synapse.patsnap.com/article/apellis-eye-drug-rejected-again-in-europehttps://synapse.patsnap.com/drug/d5606239b4084a65b883dc93cd1eaf31https://synapse.patsnap.com/drug/3b3c18bc60df475e8044080fdd93f48bhttps://synapse.patsnap.com/drug/25f88cfc4c6845e68233f9f595f15da5https://synapse.patsnap.com/drug/23e6c91bd0174f0ba6f83aeca046132ehttps://synapse.patsnap.com/article/what-is-azr-md-001-used-forhttps://synapse.patsnap.com/article/mage-biologics-begins-phase-1-trial-dosing-of-mb-001-for-inflammatory-bowel-diseasehttps://synapse.patsnap.com/blog/exploring-kt-333s-randd-successes-and-its-clinical-results-at-the-2023-ashhttps://synapse.patsnap.com/drug/3b36e2658cac4568b6c9abcfeba9f8d6https://synapse.patsnap.com/drug/672d62dd30ab401d9b63fbb61a91fc05https://synapse.patsnap.com/article/modernas-mrna-drug-joins-fda-rare-disease-acceleratorhttps://synapse.patsnap.com/drug/676093cf1fad44238eea8aaaf75f7f5dhttps://synapse.patsnap.com/drug/757925b954644464a1cbeec8ca06b83fhttps://synapse.patsnap.com/article/what-is-tropisetron-hydrochloride-used-forhttps://synapse.patsnap.com/article/aslan-pharmaceuticals-files-for-voluntary-liquidation-of-itself-and-its-subsidiaryhttps://synapse.patsnap.com/article/the-patent-landscape-of-amlodipinehttps://synapse.patsnap.com/drug/e0878686e73450c78d711145273e2b53https://synapse.patsnap.com/drug/4d51ed5daead458c99bc5d276bebddbdhttps://synapse.patsnap.com/article/nucana-halts-phase-2-due-to-unlikely-endpoint-successhttps://synapse.patsnap.com/drug/5217cedd9c254daa862ee8e62c566643https://synapse.patsnap.com/drug/e9a5e650701f4222ac507a22e0e86b27https://synapse.patsnap.com/article/daiichi-sankyo-secures-nsclc-breakthrough-designationhttps://synapse.patsnap.com/article/what-is-the-mechanism-of-clofoctolhttps://synapse.patsnap.com/article/are-there-any-biosimilars-available-for-atezolizumab